GlassScriptPhysician profile
Fabiola Anglade-Pascal
NPI 1326587908
$1,719.51
in general payments reported to CMS, 2019-2025
19 companies · $31.92 in 2025
The $31.92 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $119 · 2023: $490 · 2024: $726 · 2025: $31.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $329.14 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $217.76 | 2023-2025 | |
| Amgen INC. | $124.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Neurocrine Biosciences, INC. | $119.48 | 2023-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.22 | 2023-2024 | Caplyta |
| Genentech USA, INC. | $102.40 | 2021 | |
| Lilly USA, LLC | $98.16 | 2022 | |
| Axsome Therapeutics, INC. | $84.07 | 2023-2024 | Auvelity, Sunosi |
| Alkermes, INC. | $70.24 | 2023-2024 | Aristada, Lybalvi |
| Corium, LLC | $64.76 | 2024 | Azstarys |
| Lundbeck LLC | $63.18 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $46.55 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $38.72 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $35.72 | 2023-2024 | Austedo Xr, Austedo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $31.23 | 2023 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $29.39 | 2024 | Invega Trinza, Invega Sustenna |
| Abbott Laboratories | $21.32 | 2022 | |
| Almatica Pharma LLC | $14.19 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabiola Anglade-Pascal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.